Acute External Ventricular Drain Market by Product Type (Disposable Kits, Reusable Systems), Technology (Closed Systems, Open Systems), Drainage Type, Patient Age Group, Application, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Acute External Ventricular Drain Market was valued at USD 266.65 million in 2024 and is projected to grow to USD 293.93 million in 2025, with a CAGR of 10.54%, reaching USD 594.45 million by 2032.
Strategic introduction outlining how clinical requirements, operational pressures, and technological advancements are reshaping acute external ventricular drain utilization across care settings
Acute external ventricular drains serve as indispensable tools in contemporary neurosurgical practice, enabling cerebrospinal fluid diversion, intracranial pressure monitoring, and targeted therapeutic drainage in critically ill patients. Over recent years, clinicians and hospital systems have intensified scrutiny of device-level infection risks, procedural ergonomics, and integration with electronic monitoring systems, prompting manufacturers to refine design trade-offs between disposability, reusability, and system complexity. In parallel, advances in materials science and infection prevention protocols have shifted procurement conversations from unit price alone to total cost of ownership and patient safety outcomes.
Clinicians increasingly demand devices that streamline bedside workflows while minimizing contamination risk and enabling reliable pressure readings. As such, product development has trended toward closed systems and enhanced securement features, while health systems pursue standardized protocols and enhanced training to reduce variability in outcomes. This introduction frames the subsequent analysis by highlighting how clinical needs, operational pressures, and technological maturation converge to redefine expectations for acute external ventricular drain solutions across care settings.
Analysis of converging clinical, technological, and procurement forces that are driving safety-focused innovation and operational redesign in acute external ventricular drain solutions
Recent transformative shifts in the acute external ventricular drain landscape are driven by intersecting clinical, technological, and procurement forces that elevate safety, usability, and interoperability as principal differentiators. Clinically, heightened emphasis on infection prevention and monitoring fidelity has accelerated adoption of single-use components and closed-system architectures that reduce handling and contamination risk. Technologically, the integration of digital intracranial pressure telemetry and compatibility with electronic health records has begun to transform drains from passive devices into nodes within broader patient-monitoring ecosystems, enabling richer trend analysis and remote oversight.
Operationally, supply chain resilience and lean inventory strategies have prompted hospitals and distributors to reassess the balance between reusable systems and disposable kits, favoring solutions that reduce turnover time and sterilization burden. Concurrently, regulatory scrutiny around device labeling and post-market surveillance has pushed manufacturers to strengthen human factors engineering and provide robust training materials. These shifts collectively favor manufacturers who can deliver clinically robust, user-friendly, and interoperable solutions while healthcare providers reframe procurement around life-cycle outcomes rather than acquisition cost alone.
Assessment of how United States tariff adjustments in 2025 have reshaped sourcing strategies, supplier localization priorities, and procurement risk management for critical neurosurgical devices
The cumulative effects of tariff policy changes implemented by the United States in 2025 have introduced new considerations across procurement, manufacturing strategy, and global supply chain orchestration for acute external ventricular drain stakeholders. In the short term, increased duties on certain imported components have elevated landed costs for devices that rely on specialized catheters, valves, and electronic monitoring modules sourced from overseas suppliers. Procurement teams have responded by reassessing supplier portfolios, expanding qualification of domestic or nearshore manufacturers, and negotiating inventory buffering to ensure clinical continuity.
Over time, these trade measures have incentivized manufacturers to localize critical component production or to redesign assemblies to incorporate domestically available subcomponents, thereby mitigating tariff exposure and shortening lead times. At the same time, buyers have intensified contract language around price adjustments and supply guarantees, and capital planning has shifted to account for potential unit cost variability driven by policy shifts. Importantly, hospitals and integrated delivery networks are prioritizing supplier partnerships that demonstrate resilient sourcing strategies and transparent cost structures to manage procurement risk without compromising clinical performance.
In-depth segmentation analysis linking distinct clinical use-cases, device architectures, and channel dynamics to targeted commercialization and product development imperatives
Segmentation insights reveal distinct clinical and commercial vectors that should guide product positioning and go-to-market strategies. Across applications, device requirements vary substantially between hydrocephalus management, intracranial pressure monitoring, subarachnoid hemorrhage treatment, and traumatic brain injury management, creating opportunities for differentiated feature sets and specialized training bundles. End-user dynamics are equally influential; hospitals demand integrated solutions that align with institutional protocols, ambulatory surgical centers seek streamlined systems that minimize turnaround, and specialty clinics emphasize ease of use and portability. Product type differentiation between disposable kits and reusable systems shapes procurement conversations: disposable kits, whether advanced or standard, respond to infection control and workflow imperatives, while reusable systems, whether multi-component or single-component, appeal to buyers prioritizing capital durability and long-term cost containment.
Technology choices bifurcate around closed versus open systems, where closed systems are preferred for infection mitigation and closed-circuit monitoring, while open systems can afford procedural flexibility in certain clinical scenarios. Drainage modality-continuous versus intermittent-affects nursing protocols, bedside monitoring needs, and device durability considerations. Patient age group segmentation highlights distinct design and clinical training requirements for adult versus pediatric populations, with pediatric care demanding smaller gauges, securement strategies, and dosing considerations. Finally, distribution channel configuration, spanning distributors, ecommerce, and hospital vendors, shapes availability and service models; distributors include medical device and pharmaceutical distributors, ecommerce encompasses both manufacturer and third-party websites, and hospital vendors range from direct hospital contracts to group purchasing organizations, each requiring tailored commercial approaches.
Regional perspectives on regulatory complexity, procurement behaviors, and supply chain strategies that influence commercial success across the Americas, Europe Middle East & Africa, and Asia-Pacific
Regional dynamics present nuanced implications for regulatory pathways, reimbursement paradigms, and supply chain configuration that manufacturers and purchasers must reconcile. In the Americas, mature clinical protocols, consolidated hospital systems, and advanced critical care infrastructure create demand for integrated monitoring solutions and tight post-market surveillance expectations. Supply chains in this region trend toward nearshoring and strategic stocking to maintain continuity in high-acuity settings. In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and procurement models generates both challenges and opportunities: centralized purchasing in some markets delivers volume but requires rigorous compliance, while other jurisdictions prioritize cost containment and localized clinical validation.
Across Asia-Pacific, rapid infrastructure investments, growing neurosurgical capacity, and diverse healthcare delivery models foster demand for both cost-effective disposable kits and advanced reusable systems tailored to local clinical practice. Manufacturers operating in the region often balance global design standards with regional adaptations for size, sterilization workflows, and training materials. Collectively, these regional contrasts underline the necessity for geographically differentiated commercial strategies, adaptable regulatory plans, and flexible manufacturing footprints that respond to local clinical expectations and procurement behaviors.
Competitive landscape analysis showing how design innovation, clinical evidence generation, and service-oriented partnerships are redefining vendor differentiation in neurosurgical drainage solutions
Competitive dynamics in the acute external ventricular drain space are shaped by the interplay of design differentiation, clinical evidence, and service models that reduce procedural variability. Leading device producers are investing in human factors testing, sealed closed-system architectures, and digital monitoring adjuncts to demonstrate advantages in infection prevention and data fidelity. New entrants and niche suppliers are leveraging single-use consumables and simplified kits to address the needs of high-volume centers seeking to minimize turnaround and sterilization burden. Service-oriented companies are bundling training, clinical support, and warranty offerings to enhance adoption and reduce user error.
Partnerships between manufacturers and hospital systems have become more strategic, focusing on collaborative pilots, real-world evidence generation, and shared value agreements that link device selection to clinical quality metrics. Additionally, third-party logistics providers and specialized distributors play a growing role in ensuring device availability and in facilitating just-in-time delivery models that suit modern inventory management. Overall, companies that combine robust clinical data, thoughtful ergonomics, and reliable supply chain execution are better positioned to capture long-term clinical and institutional partnerships.
Actionable recommendations for manufacturers and healthcare systems to strengthen device safety, supply resilience, commercialization focus, and clinical adoption pathways
Industry leaders should prioritize a set of pragmatic, actionable measures to navigate clinical demand, regulatory expectations, and supply chain volatility. First, accelerate investment in human factors engineering and closed-system designs that demonstrably reduce infection risk and simplify bedside workflows, while concurrently building clinical evidence through multicenter usability studies and registries. Second, develop flexible sourcing strategies that combine regional manufacturing nodes with validated nearshore suppliers to mitigate tariff and logistic exposures, and update procurement contracts to include contingency clauses and transparent cost pass-through mechanisms. Third, tailor commercial strategies by segment: offer modular product portfolios for hydrocephalus versus trauma indications, and craft channel-specific programs for distributors, ecommerce platforms, and direct hospital vendors that reflect differing purchasing cycles and service expectations.
Additionally, strengthen post-market surveillance and training platforms to support adoption and reduce variability in clinical outcomes, and explore digital monitoring integrations that add measurable operational value. Finally, engage payers and hospital value committees early to align device selection with clinical protocols and quality metrics, thereby facilitating acceptance and reducing administrative friction during procurement decisions.
Transparent mixed-method research methodology combining clinical literature, regulatory analysis, stakeholder interviews, and usability evaluation to derive actionable insights
The research approach combines a structured review of clinical literature, regulatory guidance, and supplier filings with qualitative stakeholder interviews and device usability assessments to ensure robust evidence synthesis. Clinical literature was examined to extract device usage patterns, infection control recommendations, and monitoring best practices, while regulatory documents were analyzed to map approval pathways and post-market obligations. Supplier technical specifications, training materials, and procurement case studies were reviewed to understand commercial models and product differentiation. In parallel, interviews with clinicians, procurement leaders, and distribution partners provided real-world perspectives on device selection drivers, workflow constraints, and supply chain challenges.
Where applicable, device usability trials and human factors evaluations were incorporated to validate ergonomics and training needs. Finally, cross-referencing of regional regulatory frameworks and procurement mechanisms informed geographic segmentation and strategy recommendations. This mixed-methods approach ensures that conclusions and recommendations are grounded in both evidence and practitioner experience, supporting pragmatic decision-making for clinical and commercial stakeholders.
Concluding synthesis highlighting how safety-driven innovation, evidence-based differentiation, and supply resilience collectively determine future leadership in neurosurgical drainage solutions
In summary, acute external ventricular drain technologies are in the midst of an evolution defined by heightened infection control priorities, closer integration with digital monitoring, and supply chain recalibration in response to policy shifts. The confluence of clinical demand for safer, easier-to-use devices and commercial pressure to optimize total cost and availability has created a competitive environment where differentiation derives from demonstrable clinical outcomes and operational value. Stakeholders who align product design with clinician workflows, strengthen evidence generation, and adopt resilient sourcing models will be best positioned to meet the expectations of modern neurosurgical care.
Looking ahead, device adopters and manufacturers alike should view the field through a lifecycle lens, prioritizing solutions that reduce procedural variability, integrate meaningful monitoring data, and deliver predictable supply. By doing so, healthcare systems can improve patient safety and operational efficiency while device firms can establish durable partnerships built on clinical credibility and supply reliability.
Note: PDF & Excel + Online Access - 1 Year
Strategic introduction outlining how clinical requirements, operational pressures, and technological advancements are reshaping acute external ventricular drain utilization across care settings
Acute external ventricular drains serve as indispensable tools in contemporary neurosurgical practice, enabling cerebrospinal fluid diversion, intracranial pressure monitoring, and targeted therapeutic drainage in critically ill patients. Over recent years, clinicians and hospital systems have intensified scrutiny of device-level infection risks, procedural ergonomics, and integration with electronic monitoring systems, prompting manufacturers to refine design trade-offs between disposability, reusability, and system complexity. In parallel, advances in materials science and infection prevention protocols have shifted procurement conversations from unit price alone to total cost of ownership and patient safety outcomes.
Clinicians increasingly demand devices that streamline bedside workflows while minimizing contamination risk and enabling reliable pressure readings. As such, product development has trended toward closed systems and enhanced securement features, while health systems pursue standardized protocols and enhanced training to reduce variability in outcomes. This introduction frames the subsequent analysis by highlighting how clinical needs, operational pressures, and technological maturation converge to redefine expectations for acute external ventricular drain solutions across care settings.
Analysis of converging clinical, technological, and procurement forces that are driving safety-focused innovation and operational redesign in acute external ventricular drain solutions
Recent transformative shifts in the acute external ventricular drain landscape are driven by intersecting clinical, technological, and procurement forces that elevate safety, usability, and interoperability as principal differentiators. Clinically, heightened emphasis on infection prevention and monitoring fidelity has accelerated adoption of single-use components and closed-system architectures that reduce handling and contamination risk. Technologically, the integration of digital intracranial pressure telemetry and compatibility with electronic health records has begun to transform drains from passive devices into nodes within broader patient-monitoring ecosystems, enabling richer trend analysis and remote oversight.
Operationally, supply chain resilience and lean inventory strategies have prompted hospitals and distributors to reassess the balance between reusable systems and disposable kits, favoring solutions that reduce turnover time and sterilization burden. Concurrently, regulatory scrutiny around device labeling and post-market surveillance has pushed manufacturers to strengthen human factors engineering and provide robust training materials. These shifts collectively favor manufacturers who can deliver clinically robust, user-friendly, and interoperable solutions while healthcare providers reframe procurement around life-cycle outcomes rather than acquisition cost alone.
Assessment of how United States tariff adjustments in 2025 have reshaped sourcing strategies, supplier localization priorities, and procurement risk management for critical neurosurgical devices
The cumulative effects of tariff policy changes implemented by the United States in 2025 have introduced new considerations across procurement, manufacturing strategy, and global supply chain orchestration for acute external ventricular drain stakeholders. In the short term, increased duties on certain imported components have elevated landed costs for devices that rely on specialized catheters, valves, and electronic monitoring modules sourced from overseas suppliers. Procurement teams have responded by reassessing supplier portfolios, expanding qualification of domestic or nearshore manufacturers, and negotiating inventory buffering to ensure clinical continuity.
Over time, these trade measures have incentivized manufacturers to localize critical component production or to redesign assemblies to incorporate domestically available subcomponents, thereby mitigating tariff exposure and shortening lead times. At the same time, buyers have intensified contract language around price adjustments and supply guarantees, and capital planning has shifted to account for potential unit cost variability driven by policy shifts. Importantly, hospitals and integrated delivery networks are prioritizing supplier partnerships that demonstrate resilient sourcing strategies and transparent cost structures to manage procurement risk without compromising clinical performance.
In-depth segmentation analysis linking distinct clinical use-cases, device architectures, and channel dynamics to targeted commercialization and product development imperatives
Segmentation insights reveal distinct clinical and commercial vectors that should guide product positioning and go-to-market strategies. Across applications, device requirements vary substantially between hydrocephalus management, intracranial pressure monitoring, subarachnoid hemorrhage treatment, and traumatic brain injury management, creating opportunities for differentiated feature sets and specialized training bundles. End-user dynamics are equally influential; hospitals demand integrated solutions that align with institutional protocols, ambulatory surgical centers seek streamlined systems that minimize turnaround, and specialty clinics emphasize ease of use and portability. Product type differentiation between disposable kits and reusable systems shapes procurement conversations: disposable kits, whether advanced or standard, respond to infection control and workflow imperatives, while reusable systems, whether multi-component or single-component, appeal to buyers prioritizing capital durability and long-term cost containment.
Technology choices bifurcate around closed versus open systems, where closed systems are preferred for infection mitigation and closed-circuit monitoring, while open systems can afford procedural flexibility in certain clinical scenarios. Drainage modality-continuous versus intermittent-affects nursing protocols, bedside monitoring needs, and device durability considerations. Patient age group segmentation highlights distinct design and clinical training requirements for adult versus pediatric populations, with pediatric care demanding smaller gauges, securement strategies, and dosing considerations. Finally, distribution channel configuration, spanning distributors, ecommerce, and hospital vendors, shapes availability and service models; distributors include medical device and pharmaceutical distributors, ecommerce encompasses both manufacturer and third-party websites, and hospital vendors range from direct hospital contracts to group purchasing organizations, each requiring tailored commercial approaches.
Regional perspectives on regulatory complexity, procurement behaviors, and supply chain strategies that influence commercial success across the Americas, Europe Middle East & Africa, and Asia-Pacific
Regional dynamics present nuanced implications for regulatory pathways, reimbursement paradigms, and supply chain configuration that manufacturers and purchasers must reconcile. In the Americas, mature clinical protocols, consolidated hospital systems, and advanced critical care infrastructure create demand for integrated monitoring solutions and tight post-market surveillance expectations. Supply chains in this region trend toward nearshoring and strategic stocking to maintain continuity in high-acuity settings. In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and procurement models generates both challenges and opportunities: centralized purchasing in some markets delivers volume but requires rigorous compliance, while other jurisdictions prioritize cost containment and localized clinical validation.
Across Asia-Pacific, rapid infrastructure investments, growing neurosurgical capacity, and diverse healthcare delivery models foster demand for both cost-effective disposable kits and advanced reusable systems tailored to local clinical practice. Manufacturers operating in the region often balance global design standards with regional adaptations for size, sterilization workflows, and training materials. Collectively, these regional contrasts underline the necessity for geographically differentiated commercial strategies, adaptable regulatory plans, and flexible manufacturing footprints that respond to local clinical expectations and procurement behaviors.
Competitive landscape analysis showing how design innovation, clinical evidence generation, and service-oriented partnerships are redefining vendor differentiation in neurosurgical drainage solutions
Competitive dynamics in the acute external ventricular drain space are shaped by the interplay of design differentiation, clinical evidence, and service models that reduce procedural variability. Leading device producers are investing in human factors testing, sealed closed-system architectures, and digital monitoring adjuncts to demonstrate advantages in infection prevention and data fidelity. New entrants and niche suppliers are leveraging single-use consumables and simplified kits to address the needs of high-volume centers seeking to minimize turnaround and sterilization burden. Service-oriented companies are bundling training, clinical support, and warranty offerings to enhance adoption and reduce user error.
Partnerships between manufacturers and hospital systems have become more strategic, focusing on collaborative pilots, real-world evidence generation, and shared value agreements that link device selection to clinical quality metrics. Additionally, third-party logistics providers and specialized distributors play a growing role in ensuring device availability and in facilitating just-in-time delivery models that suit modern inventory management. Overall, companies that combine robust clinical data, thoughtful ergonomics, and reliable supply chain execution are better positioned to capture long-term clinical and institutional partnerships.
Actionable recommendations for manufacturers and healthcare systems to strengthen device safety, supply resilience, commercialization focus, and clinical adoption pathways
Industry leaders should prioritize a set of pragmatic, actionable measures to navigate clinical demand, regulatory expectations, and supply chain volatility. First, accelerate investment in human factors engineering and closed-system designs that demonstrably reduce infection risk and simplify bedside workflows, while concurrently building clinical evidence through multicenter usability studies and registries. Second, develop flexible sourcing strategies that combine regional manufacturing nodes with validated nearshore suppliers to mitigate tariff and logistic exposures, and update procurement contracts to include contingency clauses and transparent cost pass-through mechanisms. Third, tailor commercial strategies by segment: offer modular product portfolios for hydrocephalus versus trauma indications, and craft channel-specific programs for distributors, ecommerce platforms, and direct hospital vendors that reflect differing purchasing cycles and service expectations.
Additionally, strengthen post-market surveillance and training platforms to support adoption and reduce variability in clinical outcomes, and explore digital monitoring integrations that add measurable operational value. Finally, engage payers and hospital value committees early to align device selection with clinical protocols and quality metrics, thereby facilitating acceptance and reducing administrative friction during procurement decisions.
Transparent mixed-method research methodology combining clinical literature, regulatory analysis, stakeholder interviews, and usability evaluation to derive actionable insights
The research approach combines a structured review of clinical literature, regulatory guidance, and supplier filings with qualitative stakeholder interviews and device usability assessments to ensure robust evidence synthesis. Clinical literature was examined to extract device usage patterns, infection control recommendations, and monitoring best practices, while regulatory documents were analyzed to map approval pathways and post-market obligations. Supplier technical specifications, training materials, and procurement case studies were reviewed to understand commercial models and product differentiation. In parallel, interviews with clinicians, procurement leaders, and distribution partners provided real-world perspectives on device selection drivers, workflow constraints, and supply chain challenges.
Where applicable, device usability trials and human factors evaluations were incorporated to validate ergonomics and training needs. Finally, cross-referencing of regional regulatory frameworks and procurement mechanisms informed geographic segmentation and strategy recommendations. This mixed-methods approach ensures that conclusions and recommendations are grounded in both evidence and practitioner experience, supporting pragmatic decision-making for clinical and commercial stakeholders.
Concluding synthesis highlighting how safety-driven innovation, evidence-based differentiation, and supply resilience collectively determine future leadership in neurosurgical drainage solutions
In summary, acute external ventricular drain technologies are in the midst of an evolution defined by heightened infection control priorities, closer integration with digital monitoring, and supply chain recalibration in response to policy shifts. The confluence of clinical demand for safer, easier-to-use devices and commercial pressure to optimize total cost and availability has created a competitive environment where differentiation derives from demonstrable clinical outcomes and operational value. Stakeholders who align product design with clinician workflows, strengthen evidence generation, and adopt resilient sourcing models will be best positioned to meet the expectations of modern neurosurgical care.
Looking ahead, device adopters and manufacturers alike should view the field through a lifecycle lens, prioritizing solutions that reduce procedural variability, integrate meaningful monitoring data, and deliver predictable supply. By doing so, healthcare systems can improve patient safety and operational efficiency while device firms can establish durable partnerships built on clinical credibility and supply reliability.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of antimicrobial-coated catheters to reduce EVD-related infections and complications
- 5.2. Integration of wireless intracranial pressure monitoring with EVD systems for real-time neurocritical care data
- 5.3. Increasing demand for single-use disposable ventricular drains to minimize cross-contamination risks
- 5.4. Development of minimally invasive catheter insertion techniques to shorten ICU stays in neurocritical patients
- 5.5. Expansion of telemedicine-enabled EVD management platforms for remote monitoring and consultation
- 5.6. Growing investments in smart external ventricular drain systems with pressure sensors and automated drainage control algorithms
- 5.7. Regulatory approvals for novel silver-coated drains targeting multi-drug resistant pathogens in neurosurgical care
- 5.8. Collaborations between device manufacturers and AI developers to optimize EVD placement and flow adjustment protocols in critical care
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Acute External Ventricular Drain Market, by Product Type
- 8.1. Disposable Kits
- 8.1.1. Advanced Kits
- 8.1.2. Standard Kits
- 8.2. Reusable Systems
- 8.2.1. Multi Component Systems
- 8.2.2. Single Component Systems
- 9. Acute External Ventricular Drain Market, by Technology
- 9.1. Closed Systems
- 9.2. Open Systems
- 10. Acute External Ventricular Drain Market, by Drainage Type
- 10.1. Continuous Drainage
- 10.2. Intermittent Drainage
- 11. Acute External Ventricular Drain Market, by Patient Age Group
- 11.1. Adult
- 11.2. Pediatric
- 12. Acute External Ventricular Drain Market, by Application
- 12.1. Hydrocephalus Management
- 12.2. Intracranial Pressure Monitoring
- 12.3. Subarachnoid Hemorrhage Treatment
- 12.4. Traumatic Brain Injury Management
- 13. Acute External Ventricular Drain Market, by End User
- 13.1. Ambulatory Surgical Centers
- 13.2. Hospitals
- 13.3. Specialty Clinics
- 14. Acute External Ventricular Drain Market, by Distribution Channel
- 14.1. Distributors
- 14.1.1. Medical Device Distributors
- 14.1.2. Pharmaceutical Distributors
- 14.2. Ecommerce
- 14.2.1. Manufacturer Websites
- 14.2.2. Third Party Websites
- 14.3. Hospital Vendors
- 14.3.1. Direct Hospital Contracts
- 14.3.2. Group Purchasing Organizations
- 15. Acute External Ventricular Drain Market, by Region
- 15.1. Americas
- 15.1.1. North America
- 15.1.2. Latin America
- 15.2. Europe, Middle East & Africa
- 15.2.1. Europe
- 15.2.2. Middle East
- 15.2.3. Africa
- 15.3. Asia-Pacific
- 16. Acute External Ventricular Drain Market, by Group
- 16.1. ASEAN
- 16.2. GCC
- 16.3. European Union
- 16.4. BRICS
- 16.5. G7
- 16.6. NATO
- 17. Acute External Ventricular Drain Market, by Country
- 17.1. United States
- 17.2. Canada
- 17.3. Mexico
- 17.4. Brazil
- 17.5. United Kingdom
- 17.6. Germany
- 17.7. France
- 17.8. Russia
- 17.9. Italy
- 17.10. Spain
- 17.11. China
- 17.12. India
- 17.13. Japan
- 17.14. Australia
- 17.15. South Korea
- 18. Competitive Landscape
- 18.1. Market Share Analysis, 2024
- 18.2. FPNV Positioning Matrix, 2024
- 18.3. Competitive Analysis
- 18.3.1. Argi Group GmbH
- 18.3.2. B. Braun Melsungen AG
- 18.3.3. Christoph Miethke GmbH & Co. KG
- 18.3.4. DePuy Synthes
- 18.3.5. Elektron Instruments LLP
- 18.3.6. Hanni Medizintechnik GmbH
- 18.3.7. Head Sense Medical, Inc.
- 18.3.8. Integra LifeSciences Holdings Corporation
- 18.3.9. LivaNova PLC
- 18.3.10. Medtronic plc
- 18.3.11. Möller Medical GmbH
- 18.3.12. Natus Medical Incorporated
- 18.3.13. Neurologic Ltd.
- 18.3.14. Raumedic AG
- 18.3.15. Sophysa SA
- 18.3.16. Spiegelberg GmbH & Co. KG
- 18.3.17. Stryker Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
